Study guide
12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
Key Takeaways Explain This Topic AI
OSHA rules that apply to compounding include the Hazard Communication Standard (16-section Safety Data Sheets), the Bloodborne Pathogens Standard, and the eyewash requirement usually met with ANSI/ISEA Z358.1 units: reachable within 10 seconds, with tepid water for 15 minutes.
USP <797> forbids plumbed eyewashes (and other plumbed water sources) in the ISO Class 7 buffer room, while USP <800> requires an eyewash station or other emergency safety measures to be readily available.
RCRA hazardous waste includes P-listed acutely hazardous drugs (e.g., arsenic trioxide, warfarin above 0.3%), U-listed toxic drugs (e.g., cyclophosphamide, melphalan, mitomycin C) and characteristic D-code wastes. Under Subpart P, containers emptied by normal practice, even P-listed ones, are RCRA-empty.
Trace-contaminated items (RCRA-empty containers, used PPE, wipes) usually go to yellow trace-chemotherapy containers for incineration, while bulk HD waste and spill debris go to black RCRA hazardous waste containers.
HD spills are handled by trained staff with spill kits, chemotherapy gloves, gowns, goggles and a respirator (a full-facepiece cartridge respirator or PAPR for large spills), followed by deactivation, decontamination, cleaning and disinfection.
Last updated: September 2026
12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
Note
Executive Summary: Compounding personnel handle dangerous chemicals, biological agents, and antineoplastic pharmaceuticals daily. Protecting healthcare workers demands rigorous adherence to federal Occupational Safety and Health Administration (OSHA) standards, American National Standards Institute (ANSI) engineering specifications, and United States Pharmacopeia (USP) General Chapter <800> hazardous drug handling mandates. Furthermore, the Environmental Protection Agency (EPA) Resource Conservation and Recovery Act (RCRA) strictly governs pharmaceutical waste disposal. Sterile compounding pharmacists must master waste segregation rules—differentiating yellow trace from black bulk RCRA waste—and execute validated hazardous drug spill containment protocols.
Occupational Safety & OSHA Standards in Compounding Facilities
Personnel operating in sterile compounding environments face chemical toxicity, carcinogenic exposure, reproductive hazards, and infectious biological risks. OSHA enforces mandatory workplace safety regulations under Title 29 Code of Federal Regulations:
1. OSHA Hazard Communication Standard (HCS, 29 CFR 1910.1200)
The Hazard Communication Standard—known as the "Right to Know" and "Right to Understand" law—mandates that employers classify chemical hazards and communicate safety measures through standardized labeling and Safety Data Sheets (SDSs):
GHS Chemical Labeling & Pictograms: All bulk active ingredients, chemical solvents, and disinfectants must carry Globally Harmonized System (GHS) labels featuring standardized signal words ( "DANGER" or "WARNING" ), hazard statements, and pictograms. In compounding cleanrooms, common pictograms include Health Hazard (carcinogenicity, mutagenicity, reproductive toxicity of hazardous drugs), Corrosion (skin burns and eye damage from concentrated cleaning agents), and Flame (flammable cleaning alcohols and organic solvents).
Standardized 16-Section Safety Data Sheets (SDSs): OSHA mandates that chemical manufacturers and distributors structure SDSs into 16 standardized sections. Compounding personnel must be intimately familiar with key clinical sections:
Section 1: Identification (chemical identity, manufacturer emergency telephone).
Section 2: Hazard(s) Identification (GHS classification, target organ toxicity).
Section 4: First-Aid Measures (immediate emergency protocols for eye, dermal, inhalation, or ingestion exposure).
Section 8: Exposure Controls / Personal Protection (OSHA Permissible Exposure Limits [PELs], ACGIH Threshold Limit Values [TLVs], mandated ventilation controls, and specific personal protective equipment).
Section 11: Toxicological Information (acute and chronic toxicity, teratogenicity, IARC carcinogenicity classifications).
Accessibility Mandate: Safety Data Sheets must be readily accessible to all compounding, nursing, and environmental cleaning personnel across all operational shifts without administrative delays, individual management requests, or password hurdles.
2. Bloodborne Pathogen Standard (29 CFR 1910.1030)
Applies to personnel who compound or handle human blood components, autologous serum ophthalmic drops, blood fractions, or sharp devices:
Written Exposure Control Plan: Facilities must maintain a written plan, reviewed and updated at least annually, detailing exposure determinations, safe needle devices, and post-exposure management.
Engineering Controls: Mandatory implementation of puncture-resistant sharps disposal containers, needleless transfer systems, and engineered safety needles.
Hepatitis B Vaccination: Employers must offer the Hepatitis B vaccination series free of charge to all occupationally exposed employees within 10 working days of initial cleanroom assignment.
3. Emergency Eyewash and Shower Standards (ANSI/ISEA Z358.1)
Accidental chemical splashes to the ocular mucosa require immediate irrigation to prevent permanent corneal burns or systemic chemical absorption. ANSI/ISEA Z358.1 establishes mandatory engineering parameters:
Accessibility & Travel Time: An emergency eyewash station must be accessible within 10 seconds of unobstructed travel (approximately 55 feet ) from hazardous compounding areas.
Tepid Fluid Delivery: Eyewash units must deliver tepid flushing fluid maintained within the temperature range of 60 ∘ F 60^\circ\text{F} 6 0 ∘ F to 100 ∘ F 100^\circ\text{F} 10 0 ∘ F ( 16 ∘ C 16^\circ\text{C} 1 6 ∘ C to 38 ∘ C 38^\circ\text{C} 3 8 ∘ C ). Water below 60 ∘ F 60^\circ\text{F} 6 0 ∘ F induces hypothermia and causes the exposed worker to abort irrigation prematurely; water above 100 ∘ F 100^\circ\text{F} 10 0 ∘ F accelerates chemical reactivity and corneal absorption.
Flushing Duration: The station must deliver a continuous, hands-free flow of flushing fluid for a minimum of 15 minutes at a flow rate of at least 0.4 gallons per minute (1.5 L/min).
Cleanroom Architectural Placement: Water lines, drains, and open sinks represent notorious microbiological reservoirs that harbor Pseudomonas , Serratia , and fungal spores. Under USP <797> and USP <800>, plumbed eyewash stations and sink drains are strictly prohibited inside the ISO Class 7 buffer room ! Eyewash stations must be installed in the ISO Class 8 ante-room or immediately outside the cleanroom suite, or utilize closed, self-contained, certified non-draining eyewash systems engineered to prevent cleanroom bioburden release.
4. Medical Surveillance Program under USP <800>
USP <800> recommends, but does not require , a medical surveillance program for HD handlers as part of the workplace health and safety plan (USP FAQ). Components include baseline reproductive and occupational health histories, baseline physical examinations, periodic laboratory monitoring (complete blood counts, renal and hepatic profiles), biological monitoring when validated assays are available, and immediate post-exposure clinical evaluations following acute chemical spills or percutaneous injuries.
EPA RCRA Hazardous Pharmaceutical Waste Framework (40 CFR Part 261)
Pharmaceutical waste generated during compounding is governed under the federal Resource Conservation and Recovery Act (RCRA) , administered by the EPA under Title 40 Code of Federal Regulations (40 CFR Part 261). Discarding hazardous pharmaceutical waste into municipal sewer lines, sinks, or standard solid waste compactors constitutes a federal violation subject to substantial financial and civil penalties.
RCRA categorizes hazardous pharmaceutical waste into listed wastes and characteristic wastes:
1. P-Listed Hazardous Waste (Acutely Hazardous Commercial Chemical Products)
Regulatory Criteria: Discarded commercial chemical products, container residues, and spill debris containing chemicals deemed acutely hazardous by the EPA.
Representative Compounding Pharmaceuticals:
- Nicotine (P075)
- Physostigmine and physostigmine salicylate (P204)
- Arsenic trioxide (P012)
- Warfarin and salts at concentrations greater than 0.3% (P001)
The P-List Empty Container Rule: Under the general rule (40 CFR 261.7), a container that held a P-listed chemical is not empty unless triple-rinsed. EPA's 2019 healthcare rule, 40 CFR Part 266 Subpart P , changed this for pharmaceuticals. A stock, dispensing or unit-dose container (up to 1 liter or 10,000 pills) that held a P-listed pharmaceutical is RCRA-empty once its contents are removed by normal practice . A syringe is empty once fully dispensed, and an IV bag once fully administered. No triple rinse is needed. Other containers, and anything not emptied, are still managed as hazardous waste. Check whether your state has adopted Subpart P.
2. U-Listed Hazardous Waste (Toxic Commercial Chemical Products)
Regulatory Criteria: Discarded commercial chemical products and container residues containing toxic chemical substances.
Representative Compounding Pharmaceuticals (Antineoplastics & Toxic Agents):
- Cyclophosphamide (U058)
- Chlorambucil (U035)
- Melphalan (U150)
- Daunorubicin (U059)
- Streptozocin (U206)
- Mitomycin C (U010)
- Uracil mustard (U237)
- Phenol (U188)
- Lindane (U129)
The U-List Empty Container Rule: A container that previously held a U-listed substance is classified as "RCRA empty" if all contents have been removed using common practice (such as aspiration) and less than 3% of the total capacity remains by weight or volume. "RCRA empty" U-listed containers qualify as trace waste.
3. Characteristic Hazardous Waste (D-Codes)
Waste exhibiting any of four hazardous physical or chemical properties:
Ignitability (D001): Liquids with a flash point below 60 ∘ C 60^\circ\text{C} 6 0 ∘ C ( 140 ∘ F 140^\circ\text{F} 14 0 ∘ F ), or flammable compressed gases/oxidizers. Examples in compounding: alcohol solutions containing greater than 24% ethanol or isopropanol (e.g., concentrated 70% IPA solutions, ethanol-based tinctures).
Corrosivity (D002): Aqueous solutions with a pH ≤ 2.0 \text{pH} \le 2.0 pH ≤ 2.0 or pH ≥ 12.5 \text{pH} \ge 12.5 pH ≥ 12.5 . Examples: concentrated hydrochloric acid, glacial acetic acid, sodium hydroxide compounding buffers.
Reactivity (D003): Materials that are unstable, react violently with water, form potentially explosive mixtures, or release toxic cyanide or sulfide gases. Example: picric acid.
Toxicity (D004 to D043): Waste that releases heavy metals or toxic organic compounds exceeding regulatory thresholds when evaluated via the Toxicity Characteristic Leaching Procedure (TCLP). Examples: thimerosal (mercury preservative, D009), m-cresol (D024), barium salts (D005), selenium (D010).
RCRA Category Primary Regulatory Definition Key Compounding Pharmaceuticals Empty Container Disposal Standard
P-Listed Waste Acutely hazardous commercial chemical products Nicotine, physostigmine, arsenic trioxide, warfarin > 0.3 % > 0.3\% > 0.3% Under Subpart P, dispensed containers emptied by normal practice are RCRA-empty; unused drug and non-empty containers are hazardous waste
U-Listed Waste Toxic commercial chemical products (including several antineoplastics) Cyclophosphamide, melphalan, daunorubicin, mitomycin, streptozotocin "RCRA empty" when emptied by normal practice ( ≤ 3 % \le 3\% ≤ 3% residue for small containers); empty vials go to yellow trace bins
Characteristic D001 Ignitable waste; flash point < 60 ∘ C < 60^\circ\text{C} < 6 0 ∘ C ( 140 ∘ F 140^\circ\text{F} 14 0 ∘ F ) Solutions containing > 24 % > 24\% > 24% alcohol (70% IPA), flammable tinctures Managed as bulk hazardous waste if residual volume remains
Characteristic D002 Corrosive waste; pH ≤ 2.0 \text{pH} \le 2.0 pH ≤ 2.0 or pH ≥ 12.5 \text{pH} \ge 12.5 pH ≥ 12.5 Concentrated hydrochloric acid, glacial acetic acid, NaOH Neutralization prohibited without permit; discard in bulk hazardous bins
Characteristic D003/D004+ Reactive or toxic leachable chemical waste Picric acid (reactive D003); thimerosal/mercury (toxic D009) Managed as bulk hazardous waste via licensed hazardous waste transporter
Yellow Trace vs. Black Bulk RCRA Waste Segregation
Compounding facilities must maintain distinct, color-coded waste streams to prevent environmental contamination and comply with federal EPA and Department of Transportation (DOT) standards:
Yellow Waste Receptacles: Trace Chemotherapy / Regulated Medical Waste
Eligibility Criteria: Items that are contaminated with hazardous drugs but contain less than 3% residual volume ("RCRA empty").
Acceptable Items:
Empty intravenous infusion minibags and administration tubing.
RCRA-empty vials of antineoplastic agents (e.g., cyclophosphamide).
Empty syringes used for dose transfer or administration.
Contaminated personal protective equipment: chemotherapy gloves, gowns, shoe covers, masks, head covers.
Decontamination supplies: lint-free wipes, alcohol swabs, and disposable Closed System Drug-Transfer Device (CSTD) components.
Disposal & Destruction Method: Yellow containers are collected by licensed medical waste haulers and undergo high-temperature incineration at 1 , 800 ∘ F 1,800^\circ\text{F} 1 , 80 0 ∘ F to 2 , 000 ∘ F 2,000^\circ\text{F} 2 , 00 0 ∘ F at a permitted regulated medical waste incineration facility. High heat completely degrades cytotoxic molecules into non-hazardous ash and combustion gases. Autoclaving is not an appropriate treatment for trace chemotherapy waste, because steam does not destroy the drug molecules. Many states require incineration.
Black Waste Receptacles: Bulk Hazardous / RCRA Hazardous Waste
Eligibility Criteria: Any item containing greater than 3% residual volume , intact unused drug formulations, chemical spill residues, and all P-listed waste.
Mandatory Items:
Partially used vials containing more than 3% residual volume.
Expired, unadministered, or discontinued hazardous drug preparations.
Unused P-listed drugs (e.g., a partly used arsenic trioxide vial) and P-listed containers that are not RCRA-empty.
Materials collected during hazardous chemical spill clean-up (absorbent pads, spill powders, contaminated scoops).
Broken vials, leaking containers, or shattered ampules of hazardous substances.
Disposal & Destruction Method: Black containers must be manifested under a formal EPA Hazardous Waste Manifest, transported by an EPA-licensed hazardous waste transporter, and delivered to a federally licensed RCRA Treatment, Storage, and Disposal Facility (TSDF) for specialized hazardous waste incineration.
Hazardous Drug Spill Clean-up Protocol Under USP <800>
Chemical spills of hazardous drugs within cleanrooms or compounding areas pose immediate aerosolization and absorption hazards. USP <800> mandates that every facility handling hazardous drugs maintain dedicated, readily accessible hazardous drug spill kits.
Mandated Spill Kit Contents
A compliant hazardous drug spill kit must contain:
2 pairs of disposable chemotherapy gloves tested to ASTM D6978.
1 disposable impermeable polyethylene-coated chemotherapy gown.
1 NIOSH-certified respirator (N95, N99, N100, or Powered Air-Purifying Respirator [PAPR]; surgical masks provide zero respiratory protection against aerosols and are prohibited).
1 pair of chemical splash goggles (standard safety glasses lack an airtight perimeter seal and are inadequate).
1 pair of impermeable chemotherapy shoe covers.
Absorbent spill pads and chemical neutralizing/solidifying spill powder.
Non-sparking, non-reactive plastic scoops and scrapers.
Puncture-resistant sharps disposal container.
Heavy-duty disposable yellow trace and black bulk RCRA waste bags.
High-visibility warning signs stating "CAUTION: HAZARDOUS DRUG SPILL — DO NOT ENTER" .
The 8-Step Spill Clean-up Protocol
When a hazardous chemical spill occurs, personnel must immediately execute the following sequential workflow:
Evacuate & Isolate the Area: Immediately evacuate non-essential personnel from the spill area. Post prominent caution signage restricting entry and immediately notify the sterile compounding supervisor and facility safety officer.
Don Full Hazardous PPE: Don protective equipment in proper sequence: inner ASTM D6978 gloves beneath gown cuffs, impermeable chemotherapy gown, outer ASTM D6978 gloves over cuffs, chemical splash goggles, NIOSH-certified respirator, and shoe covers.
Contain & Absorb the Spill:
Liquid Spills: Gently place absorbent pads or sprinkle solidifying spill powder over the liquid. Work systematically from the outer perimeter inward toward the center to avoid spreading the contamination.
Dry Powder Spills: Gently drape damp, moist absorbent pads over the powder to prevent dry particles from aerosolizing into cleanroom laminar airflow.
Remove Mechanical Debris: Use the dedicated plastic scoops or forceps to retrieve broken glass ampules, cracked vials, or sharp debris. Never pick up broken glass with gloved hands! Deposit all sharps directly into the puncture-resistant sharps box.
Waste Bagging: Collect all saturated pads, spent spill powder, and disposable clean-up tools into heavy-duty black RCRA hazardous waste bags. Seal the bags securely.
Three-Step Surface Decontamination Sequence:
Step A: Deactivation & Decontamination: Apply an EPA-registered oxidizing agent (e.g., sodium hypochlorite 0.525% bleach solution, hydrogen peroxide, or peracetic acid) to chemically degrade and cleave the hazardous drug molecule into non-toxic compounds.
Step B: Cleaning: Apply a germicidal detergent solution to physically suspend, lift, and remove deactivated chemical byproducts, organic soils, and surfactant residues.
Step C: Disinfection: Apply sterile 70% Isopropyl Alcohol (IPA) to achieve vegetative microbial disinfection, allowing the surface to air-dry completely.
PPE Doffing & Disposal: Doff outer gloves, gown, goggles, respirator, and inner gloves in proper reverse sequence inside the isolated area. Place all contaminated PPE into the black RCRA waste bag. Immediately wash hands thoroughly with soap and water.
Incident Logging & Medical Follow-up: Document the spill incident in the facility safety log, noting chemical identity, estimated volume, root causes, and clean-up duration. If accidental skin or mucosal contact occurred, refer the exposed employee for immediate medical surveillance evaluation.